Foreign Drugmakers Now Getting More GMP Warning Letters Than U.S. Firms
This article was originally published in The Pink Sheet Daily
Executive Summary
For the first time, this fiscal year FDA seems to be on track to send more warning letters to foreign manufacturers of finished pharmaceuticals and APIs than their domestic counterparts.
You may also be interested in...
FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues
FDA could help create several international coalitions to carry out its new globalization plan, which could allow for issue-specific groups focused on individual pharmaceutical sectors.
FDA Continues Aggressive Enforcement as Drug GMP Warning Letters Mount
The Obama administration’s FDA continues to deliver on its promise of swift and aggressive enforcement of drug GMP requirements that it pronounced two years ago.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: